“Not Today”: Overcoming PrEP Hesitancy, Stigma, and Adherence Barriers With Lenacapavir

REFERENCES

1. 1.↵
   Louisiana HIV, AIDS, Early Syphilis, & Congenital Syphilis Surveillance Quarterly Report. Louisiana Department of Health Office of Public Health. March 31, 2024. Accessed June 2, 2025. ldh.la.gov/assets/oph/HIVSTD/2024-reports/First-Quarter-2024-HIV-and-Syphilis-Report.pdf
2. 2.↵
   1. Huang YA,
   2. Tao G,
   3. Smith DK,
   4. Hoover KW

   . Persistence with human immunodeficiency virus pre-exposure prophylaxis in the United States, 2012-2017. Clin Infect Dis. 2021;72(3):379-385. doi: 10.1093/cid/ciaa037

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Bekker LG,
   2. Das M,
   3. Abdool Karim Q

   , et al. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med. 2024;391(13):1179-1192. doi: 10.1056/NEJMoa2407001

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Kelley CF,
   2. Acevedo-Quiñones M,
   3. Agwu AL,
   4. et al.

   Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. N Engl J Med. 2025;392(13):1261-1276. doi: 10.1056/NEJMoa2411858

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Dombrowski JC,
   2. Donnell D,
   3. Grabow C,
   4. et al.

   Evidence-informed provision of doxycycline post-exposure prophylaxis for prevention of bacterial sexually transmitted infections. Clin Infect Dis. 2024 Oct 30:ciae527. doi: 10.1093/cid/ciae527

   OpenUrlCrossRef
6. 6.↵
   1. Jenness SM,
   2. Weiss KM,
   3. Goodreau SM,
   4. et al.

   Incidence of gonorrhea and chlamydia following human immunodeficiency virus preexposure prophylaxis among men who have sex with men: a modeling study. Clin Infect Dis. 2017;65(5):712-718. doi: 10.1093/cid/cix439

   OpenUrlCrossRefPubMed
7. 7.↵
   Yeztugo® (lenacapavir) is now the first and only FDA-approved HIV prevention option offering 6 months of protection. News release. Gilead Sciences, Inc. June 18, 2025. Accessed August 9, 2025. gilead.com/news/news-details/2025/yeztugo-lenacapavir-is-now-the-first-and-only-fda-approved-hiv-prevention-option-offering-6-months-of-protection
8. 8.↵
   Gilead signs royalty-free voluntary licensing agreements with six generic manufacturers to increase access to lenacapavir for HIV prevention in high-incidence, resource-limited countries. News release. Gilead Sciences, Inc. October 2, 2024. Accessed May 29, 2025. gilead.com/news/news-details/2024/gilead-signs-royalty-free-voluntary-licensing-agreements-with-six-generic-manufacturers-to-increase-access-to-lenacapavir-for-hiv-prevention-in-high-incidence-resource-limited-countries
9. 9.↵
   1. Wehrwein P

   . Lenacapavir HIV PrEP: not an aids vaccine, but vaccine adjacent. Managed Healthcare Executive. June 18, 2025. Accessed July 28, 2025. managedhealthcareexecutive.com/view/lenacapavir-not-an-aids-vaccine-but-vaccine-adjacent
10. 10.
    1. Dickson S,
    2. James K

    . Trends in HIV preexposure prophylaxis utilization and spending among individuals with commercial insurance. AIDS. 2024;38(4):610-612. doi: 10.1097/QAD.0000000000003809

    OpenUrlCrossRefPubMed
11. 11.↵
    What is the list price of APRETUDE? ViiV Healthcare. Accessed August 6, 2025. viivuspricing.com/apretude.html
12. 12.↵
    Questions about how much you will pay? We are here to help. Descovy. Gilead Sciences, Inc. Accessed July 29, 2025. gileadpriceinfo.com/descovy